|
|
||||||||
Cardiac Surgery, Cleveland Clinic Foundation, 9500 Euclid Ave, Desk H-35, Cleveland, OH 44122
(Email: abeel.mangi@gmail.com).
| The first 20% of the full text of this article appears below. |
Coronary artery bypass grafting in the setting of ischemic ventricular fibrillation independently protects against future episodes of ventricular arrhythmia and future episodes of sudden cardiac death [1–3]. Secondary prophylaxis by implantable cardioverter-defibrillator (ICD) resulted in 31% reduction in mortality in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial, a 23% in The Canadian Implantable Defibrillator Study (CASH) trial [4], and 20% in the Canadian Implantable Defibrillator Study (CIDS) trial [5]. In the Coronary Artery Bypass Graft (CABG) Patch trial [6], patients who were believed to be at high risk for sudden death were randomized to CABG only and
Related Article
Ann. Thorac. Surg. 2008 85: 1278-1281.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |